Pancreatic cancer in 2017

Rebooting pancreatic cancer knowledge and treatment options

High stromal cellularity in pancreatic cancer is an important factor for ineffective treatment and molecular studies. In 2017, major advancements were made in transcriptional characterization, treatment delivery and clinical regimes, raising hope for a breakthrough against this deadly disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Selected advances in pancreatic ductal adenocarcinoma during 2017.


  1. 1

    Kleeff, J. et al. Pancreatic cancer. Nat. Rev. Dis. Primers 2, 16022 (2016).

    Article  Google Scholar 

  2. 2

    Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).

    CAS  Article  Google Scholar 

  3. 3

    Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203.e13 (2017).

  4. 4

    Lord, C. J. & Ashworth, A. PARP inhibitors: synthetic lethality in the clinic. Science 355, 1152–1158 (2017).

    CAS  Article  Google Scholar 

  5. 5

    Xiong, Y. et al. Covalent guanosine mimetic inhibitors of G12C KRAS. ACS Med. Chem. Lett. 8, 61–66 (2017).

    CAS  Article  Google Scholar 

  6. 6

    Xue, W. et al. Small RNA combination therapy for lung cancer. Proc. Natl Acad. Sci. USA 11, E3553–E3561 (2014).

    Article  Google Scholar 

  7. 7

    Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).

    CAS  Article  Google Scholar 

  8. 8

    Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225–232 (2012).

    CAS  Article  Google Scholar 

  9. 9

    Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633–637 (2013).

    CAS  Article  Google Scholar 

  10. 10

    Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).

    CAS  Article  Google Scholar 

Download references


The authors are supported by DFG grant (German research Foundation) SE-2616/2-1 (Germany) to A.S. and U01DK108328, U01CA117969, U01CA196403, and P01CA117969 to A.M.

Author information



Corresponding author

Correspondence to Anirban Maitra.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Semaan, A., Maitra, A. Rebooting pancreatic cancer knowledge and treatment options. Nat Rev Gastroenterol Hepatol 15, 76–78 (2018).

Download citation

Further reading


Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing